Search results for "treatment."

showing 10 items of 17500 documents

Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran

2018

Cutaneous leishmaniasis (CL) is a serious health challenge at the global level due to Leishmania tropica. This study was conducted to evaluate the risk factors associated with anthroponotic CL (ACL) in unresponsive (patient who does not heal and remains with an active lesion, despite receiving two courses of intra-lesional Glucantime along with cryotherapy and one cycle of systemic Glucantime) and responsive patients in a major focus in southeastern Iran. A case-control study was conducted from April 2015 to October 2016 in the southeast of Iran. Patients were recruited in a major ACL focus from unresponsive and responsive cases. These patients were compared for environmental, clinical, and…

0301 basic medicineLeishmania tropicamedicine.medical_treatmentSocial Scienceslcsh:MedicineScarsCryotherapyIranPathology and Laboratory MedicineLogistic regressionPolymerase Chain ReactionGeographical Locations0302 clinical medicineRisk FactorsZoonosesMedicine and Health Scienceslcsh:ScienceLeishmaniasisProtozoansLeishmaniaMultidisciplinaryGeographybiologyEukaryotaInfectious Diseasesmedicine.symptomResearch ArticleNeglected Tropical Diseasesmedicine.medical_specialtyAsiaPatients030106 microbiology030231 tropical medicineLeishmaniasis CutaneousHuman GeographyLesion03 medical and health sciencesSigns and SymptomsCutaneous leishmaniasisDiagnostic MedicineInternal medicineParasitic DiseasesmedicineHumansProtozoan Infectionsbusiness.industrylcsh:ROrganismsHealth Risk AnalysisBiology and Life SciencesOdds ratioDNA ProtozoanTropical Diseasesmedicine.diseasebiology.organism_classificationParasitic ProtozoansConfidence intervalHealth CareAge GroupsLeishmania tropicaCase-Control StudiesPeople and PlacesLesionsEarth SciencesHousingPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Good's syndrome and recurrent leishmaniasis: A case report and review of literature

2020

We report the case of a 56-year-old Caucasian male affected by thymoma and myasthenia gravis that developed recurrent visceral leishmaniasis 11 years after thymectomy. After treatment of each relapse with liposomal amphotericin B the PCR-Leishmania was negative and the patient showed clinical improvement. An immunologic work-up was performed showing lymphopenia with an important decrease in CD4+ T cells (52 cells/μ) and CD4/CD8 ratio (0.2). HIV test was negative. On the basis of previous thymoma and myasthenia gravis and on the basis of the immunological profile a diagnosis of Good's syndrome was made. Since IFNγ plays a main role in the control of Leishmania infection the production of IFN…

0301 basic medicineLeishmaniasiThymomamedicine.medical_treatmentT cellImmunologyLiposomal amphotericin BCase ReportGood's syndromeCD4+ T cell03 medical and health sciences0302 clinical medicinemedicineIntensive care medicinelcsh:Social sciences (General)lcsh:Science (General)LeishmaniasisInternal medicineInfectious diseaseMultidisciplinarybusiness.industryLeishmaniasisImmunotherapymedicine.diseaseLaboratory medicineCD4+ T cellsMyasthenia gravisThymectomy030104 developmental biologyVisceral leishmaniasismedicine.anatomical_structureImmunologylcsh:H1-99business030217 neurology & neurosurgeryCD8IFNγlcsh:Q1-390Heliyon
researchProduct

Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children

2016

PURPOSE: The effect of growth hormone (GH) on adipose tissue and the role of adipokines in modulating metabolism are documented, but with discordant data. Our aim was to evaluate the impact of GH treatment on a series of selected adipokines known to have a metabolic role and poorly investigated in this setting. METHODS: This is a prospective study. Thirty-one prepubertal children (25 M, 6 F; aged 8.5 ± 1.6 years) with isolated GH deficiency treated with GH for at least 12 months and 30 matched controls were evaluated. Auxological and metabolic parameters, insulin sensitivity indexes, leptin, soluble leptin receptor, adiponectin, visfatin, resistin, omentin, adipocyte fatty acid-binding prot…

0301 basic medicineLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokineAdipose tissue030209 endocrinology & metabolismEnzyme-Linked Immunosorbent AssayGPI-Linked ProteinsAdipokines; Children; Growth hormone; Insulin sensitivitySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineAdipocyteLectinsAdipokinemedicineHumansResistinProspective StudiesChildNicotinamide PhosphoribosyltransferaseChildrenGrowth hormoneGrowth DisordersLeptin receptorAdiponectinbusiness.industryHuman Growth HormoneLeptinInsulinInsulin sensitivityHormones030104 developmental biologyEndocrinologychemistryCase-Control StudiesChild PreschoolCytokinesResistinFemalebusinessBiomarkers
researchProduct

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease.

2018

L-DOPA is still the most effective pharmacological therapy for the treatment of motor symptoms in Parkinson's disease (PD) almost four decades after it was first used. Deep brain stimulation (DBS) is a safe and highly effective treatment option in patients with PD. Even though a clear understanding of the mechanisms of both treatment methods is yet to be obtained, the combination of both treatments is the most effective standard evidenced-based therapy to date. Recent studies have demonstrated that DBS is a therapy option even in the early course of the disease, when first complications arise despite a rigorous adjustment of the pharmacological treatment. The unique feature of this therapeu…

0301 basic medicineLevodopaParkinson's diseaseDeep brain stimulationglobus pallidus internus (GPi)medicine.medical_treatmentParkinson's diseaseCentral nervous systemStimulationDiseaseReviewlcsh:RC346-42903 medical and health sciencesTherapeutic approach0302 clinical medicinemedicinelevodopadeep brain stimulation (DBS)lcsh:Neurology. Diseases of the nervous systembusiness.industryDopaminergicmedicine.diseasenervous system diseases030104 developmental biologymedicine.anatomical_structureNeurologyNeurology (clinical)businessNeurosciencesubthalamic nucleus (STN)030217 neurology & neurosurgerymedicine.drugFrontiers in neurology
researchProduct

Pre-dopa Deep Brain Stimulation: Is Early Deep Brain Stimulation Able to Modify the Natural Course of Parkinson’s Disease?

2020

Deep brain stimulation (DBS) is an established therapy for the management of Parkinson's disease (PD). However, DBS is indicated as the disease progresses and motor complications derived from pharmacological therapy arise. Here, we evaluate the potential of DBS prior to levodopa (L-Dopa) in improving quality of life (QoL), challenging the state of the art for DBS therapy. We present data on clinical manifestation, decision finding during early indication to DBS, and trajectories after DBS. We further discuss current paradigms for DBS and hypothesize on possible mechanisms. Six patients, between 50 and 67 years old, presenting at least 5 years of PD symptoms, and without L-Dopa therapy initi…

0301 basic medicineLevodopamedicine.medical_specialtyDeep brain stimulationParkinson's diseasemedicine.medical_treatmentDiseaselcsh:RC321-57103 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationQuality of lifemedicineAdverse effectlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchsubthalamic nucleusbusiness.industryGeneral Neuroscienceearly deep brain stimulationmedicine.diseasenervous system diseasesdeep brain stimulationClinical trialSubthalamic nucleusearly intervention030104 developmental biologysurgical procedures operativenervous systemParkinson’s diseasebusinesstherapeutics030217 neurology & neurosurgerymedicine.drugNeuroscienceFrontiers in Neuroscience
researchProduct

From waste to health: sustainable exploitation of grape pomace seed extract to manufacture antioxidant, regenerative and prebiotic nanovesicles withi…

2020

AbstractPomace seed extract loaded vesicles were prepared as promising technological and green solution to exploit agri-food wastes and by-products, and develop high value-added products for human health. An antioxidant extract rich in bioactive compounds (epicatechins, catechin, gallic acid, quercetin and procynidins) was obtained from the seeds isolated from the pomace of Cannonau red grape cultivar. The extract was incorporated into phospholipid vesicles ad hoc formulated for intestinal delivery, by combining them, for the first time, whit a maltodextrin (Glucidex). Glucidex-transfersomes, glucidex-hyalurosomes and glucidex-hyalutransferomes were prepared, characterized and tested. Gluci…

0301 basic medicineLimosilactobacillus reuteriAntioxidantmedicine.medical_treatmentlcsh:MedicinePolysorbatesAntioxidantschemistry.chemical_compound0302 clinical medicineRecyclingVitisGallic acidFood scienceHyaluronic AcidHydrogen peroxidelcsh:SciencePhospholipidsDrug CarriersMultidisciplinaryfood and beveragesCatechinMaltodextrinIntestinesPolifenolsColonic NeoplasmsSeedsQuercetinPrebiòticsGrapesArticle03 medical and health sciencesNanocapsulesNanoscience and technologyPolysaccharidesCell Line TumormedicineHumansRaïmsWaste ProductsPlant ExtractsPrebioticlcsh:RPomaceHealth carePolyphenolsGreen Chemistry TechnologyHydrogen PeroxideNanostructuresIntestinal Diseases030104 developmental biologyPrebioticschemistryBiofilmsLiposomeslcsh:Q030217 neurology & neurosurgery
researchProduct

Modeling the Hematopoietic Landscape

2019

Some time ago, we proposed a continuum-like view of the lineages open to hematopoietic stem cells (HSCs); each HSC self-renews or chooses from the spectrum of all end-cell options and can then “merely” differentiate. Having selected a cell lineage, an individual HSC may still “step sideways” to an alternative, albeit closely related, fate: HSC and their progeny therefore remain versatile. The hematopoietic cytokines erythropoietin, granulocyte colony-stimulating factor, macrophage colony-stimulating factor, granulocyte/macrophage colony-stimulating factor and ligand for the fms-like tyrosine kinase 3 instruct cell lineage. Sub-populations of HSCs express each of the cytokine receptors that …

0301 basic medicineLineage (genetic)medicine.medical_treatmentReviewBiologyCell and Developmental Biology03 medical and health sciencesimmune cells0302 clinical medicinemedicineMacrophageEpigeneticsCytokine bindinglcsh:QH301-705.5Cell Biologyhematopoiesishematopoietic stem cellsCell biologyHaematopoiesis030104 developmental biologyCytokinelcsh:Biology (General)030220 oncology & carcinogenesisDNA methylationblood cellsStem cellfate determinationDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Cryptochlorogenic acid attenuates LPS-induced inflammatory response and oxidative stress via upregulation of the Nrf2/HO-1 signaling pathway in RAW 2…

2019

Phenolic acids are found in natural plants, such as caffeic acid, rosmarinic acid, and chlorogenic acid. They have long been used as pharmacological actives, owing to their anti-inflammatory and antioxidant activities. Cryptochlorogenic acid (CCGA) is a special isomer of chlorogenic acid; the pharmacological effects and related molecular mechanisms of CCGA have been poorly reported. In the present study, the antioxidant and anti-inflammatory effects of CCGA in RAW 264.7 macrophages and the underlying mechanisms were investigated. The results revealed that CCGA dose-dependently inhibited LPS-induced production of NO, TNF-α, and IL-6 and blocked iNOS, COX-2, TNF-α, and IL-6 expressions. CCGA …

0301 basic medicineLipopolysaccharidesAntioxidantMAP Kinase Signaling SystemNF-E2-Related Factor 2medicine.medical_treatmentImmunologyAnti-Inflammatory AgentsIκB kinasemedicine.disease_causeAntioxidants03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicinemedicineCaffeic acidImmunology and AllergyAnimalsPharmacologyInflammationRosmarinic acidMacrophagesNF-kappa BMembrane ProteinsNF-κBGlutathioneCell biologyI-kappa B KinaseOxidative Stress030104 developmental biologyRAW 264.7 Cellschemistry030220 oncology & carcinogenesisSignal transductionChlorogenic AcidInflammation MediatorsOxidative stressHeme Oxygenase-1Signal TransductionInternational immunopharmacology
researchProduct

Beta3 adrenergic receptor stimulation in human macrophages inhibits NADPHoxidase activity and induces catalase expression via PPARγ activation

2017

IF 4.521; International audience; The beta3 adrenergic receptor (β3-AR) stimulation plays a protective role against preterm labor by blocking myometrial contraction, cytokine production, remodeling and apoptosis. We previously demonstrated that macrophage-induced ROS production in the myometrium was a key element leading to the induction of all these labor-associated features. We thus aimed to investigate if the β3-AR could be expressed in human macrophages and could trigger its protective role in the myometrium by directly inhibiting ROS production. Using lipopolysaccharide (LPS)-stimulated myometrial samples and cell co-culture experiments, we demonstrated that β3-AR stimulation inhibits …

0301 basic medicineLipopolysaccharidesmedicine.medical_specialtyLipopolysaccharidePPARγPreterm laborMacrophagemedicine.medical_treatmentPeroxisome proliferator-activated receptorStimulationApoptosisAntioxidants03 medical and health scienceschemistry.chemical_compoundTransactivation0302 clinical medicineInternal medicinemedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMolecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologychemistry.chemical_classificationNADPH oxidasebiologybeta3 adrenergic receptorMacrophagesMyometriumNADPH OxidasesROSCell BiologyCatalaseCoculture Techniques3. Good healthCell biologyPPAR gamma030104 developmental biologyEndocrinologyCytokinechemistryGene Expression RegulationReceptors Adrenergic beta-3biology.proteinMyometriumFemaleSignal transductionReactive Oxygen Species030217 neurology & neurosurgerySignal Transduction
researchProduct

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

2018

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score [NAS] ≥4, and liver fibrosis (stages 1-3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome was ≥2-point improvement in NAS and no worsening of fibrosis at year 1. Key secondary outcomes were: resolution of steatohepatitis and no worsening of fibrosis; improvement in fibrosis by ≥1 stag…

0301 basic medicineLiver CirrhosisMalePlacebo-controlled studyMedical Biochemistry and MetabolomicsGastroenterologyOral and gastrointestinallaw.inventionHepatitisNASH NAFLD CVC nonalcoholic fatty liver inflammationSteatohepatitis/Metabolic Liver Disease0302 clinical medicineRandomized controlled trialFibrosislawNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseeducation.field_of_studyCVCLiver DiseaseNASHImidazolesMiddle AgedTreatment OutcomeTolerabilityLiverSulfoxides6.1 PharmaceuticalsCCR5 Receptor Antagonists030211 gastroenterology & hepatologyOriginal ArticleFemalePatient SafetyAdultmedicine.medical_specialtyPopulationChronic Liver Disease and CirrhosisClinical Trials and Supportive ActivitiesClinical SciencesImmunologyPlacebo03 medical and health sciencesDouble-Blind MethodClinical ResearchInternal medicineNAFLDmedicinenonalcoholic fatty liverHumanseducationAgedHepatologyGastroenterology & Hepatologybusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articlesmedicine.diseaseequipment and suppliesSurgeryCVC; NAFLD; NASH; inflammation; nonalcoholic fatty liver030104 developmental biologyinflammationHuman medicineSteatohepatitisbusinessDigestive DiseasesBiomarkers
researchProduct